WaveBreak (www.WaveBreakTx.com) is a biopharmaceutical company focused transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. WaveBreak has built a unique drug discovery platform to target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. WaveBreak is focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Alzheimer’s disease, and ALS. WaveBreak was previously Wren Therapeutics.
View Top Employees from WaveBreak (formerly Wren Therapeutics)Website | http://www.wavebreaktx.com |
Revenue | $8 million |
Funding | $29.6 million |
Employees | 56 (56 on RocketReach) |
Founded | 2016 |
Technologies |
JavaScript,
HTML,
Twitter
+25 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Biopharma, Pharmaceuticals, Healthcare, Health Care, Science and Engineering, Pharmaceutical |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 541714 Companies, NAICS Code 54171 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies |
Looking for a particular WaveBreak (formerly Wren Therapeutics) employee's phone or email?
The WaveBreak (formerly Wren Therapeutics) annual revenue was $8 million in 2024.
56 people are employed at WaveBreak (formerly Wren Therapeutics).
WaveBreak (formerly Wren Therapeutics) is based in Cambridge, England.
The NAICS codes for WaveBreak (formerly Wren Therapeutics) are [54, 541714, 54171, 541, 5417].
The SIC codes for WaveBreak (formerly Wren Therapeutics) are [873, 87].